-
Observed outcomes by treatment arm and by the ACCORD-BP trial population’s pr...
Observed outcomes by treatment arm and by the ACCORD-BP trial population’s predicted benefit/harm (validation cohort). -
Demographic characteristics and comorbidities of HNSCC in Taiwan (n = 18243).
Demographic characteristics and comorbidities of HNSCC in Taiwan (n = 18243). -
r37980778c78--ecc0895efe03f2f06eeae815e1b0fc85
Incidence density of secondary primary cancer in aspirin users and non-aspirin users among HNSCC patients identified during 2000–2011. -
Observed outcomes by treatment arm and by benefit/harm subgroup for the SPRIN...
Observed outcomes by treatment arm and by benefit/harm subgroup for the SPRINT trial (derivation cohort) and ACCORD-BP trial (validation cohort) when applying models fit by... -
r37980778c78--0a931cd03bcbddcb42553a3fd7018d87
Baseline characteristics of the SPRINT trial participants included for model derivation (N = 9,069) and ACCORD-BP trial participants included for model validation (N = 4,498). -
Baseline characteristics of participants.
Data are presented as mean±SD, median (interquartile range) or percent. Chi-square test for categorical variables, the unpaired t test or Mann-Whitney U test for continuous... -
r37980778c78--4d99f1ab43861f80bf04e2ea9137adfc
Comparison of discrimination and calibration for models fit by elastic net regularization versus traditional backwards selection. -
r37980778c78--56905ae4677c893a88bec378abb0acf0
Risk score for harm from intensive blood pressure treatment, developed from the SPRINT trial. -
r37980778c78--8ff1da1f0b0aaee0528980600e5ff5cf
Risk score for benefit from intensive blood pressure treatment, developed from the SPRINT trial. -
The incidence density of secondary primary cancer in Aspirin users and Non-as...
The incidence density of secondary primary cancer in Aspirin users and Non-aspirin users among HNSCC patients stratified by follow-up duration. -
r37980778c78--aebdd7ae91903c50254e3dbeffed0334
Observed outcomes by treatment arm and by the SPRINT trial population’s predicted benefit/harm (derivation cohort). -
r37980778c78--30d090c64503da4540a0493d6ed51a35
BackgroundIntensive blood pressure (BP) treatment can avert cardiovascular disease (CVD) events but can cause some serious adverse events. We sought to develop and validate risk... -
r37980778c78--5500a7aa73fea9cfcc660f300b1421fe
The incidence of major secondary primary cancer in aspirin users and non-aspirin users among HNSCC patients identified during 2000–2011.
